RxDoctor Payments Data

Kateryna Kolesnikova, MD

Obstetrics & Gynecology · Hackensack, NJNPI 1023513678

Payments from drug & device makers

$3,838in general payments, 2019–2025

Across 112 payments — averaging $34.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bluewind Medical$1K
  • Astellas Pharma US Inc$415
  • Sumitomo Pharma America, Inc.$378
  • Biotissue Holdings Inc.$373
  • Hologic Sales And Service, LLC$294
  • Millicent US Inc$258
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$92624%
  • Food & beverage$2,62268%
  • Education$2908%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,838 in reported general payments places this provider in the 85th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

See all obstetrics & gynecology providers in New Jersey

Medicare billing

Part B allowed, 2024
$70,120
Medicare patients
338
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron87$60,128
Estradiol140$18,086
PremarinEstrogens, Conjugated37$15,870
YuvafemEstradiol65$9,919
IntrarosaPrasterone (Dhea)31$8,150
ImvexxyEstradiol23$7,064
Estradiol (Once Weekly)Estradiol11$1,189
Clobetasol Propionate33$1,063
Alendronate Sodium64$704
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst71$628
Metronidazole15$597
ValacyclovirValacyclovir Hcl14$363
Hydroxyzine Hcl17$120
Gabapentin13$54
Triamcinolone Acetonide14$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$378$60,12887 claims
PfizerPremarin$119$15,87037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

Other obstetrics & gynecology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →